University of Washington_Fred Hutchinson Cancer Center
Seattle, Washington 98195
19 studies enrolling now · 31 studies all time
What they study most
ALK-positive Non-small Cell Lung Cancer (NSCLC), Adenoid Cystic Carcinoma, Adenovirus, Advanced Cancer, Advanced Malignant Neoplasm, Advanced Solid Tumor, Advanced Solid Tumors, Anaplastic Lymphoma Kinase-positive, Angiosarcoma of Skin, Anogenital Cancer, Bladder Cancer, Breast Cancer
Studies at this site
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
- A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — Recruiting now
- SLV-154 Treatment of Advanced Cancers — Recruiting now
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors — Recruiting now
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors — Recruiting now
- Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression — Recruiting now
- Study of CHS-114 in Participants With Advanced Solid Tumors — Recruiting now
- Study of ORIC-944 in Patients With Metastatic Prostate Cancer — Recruiting now
- QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer — Recruiting now
- A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies — Recruiting now
- HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor — Recruiting now
- SLV-324 Treatment of Metastatic Solid Tumors — Recruiting now
- A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) — Recruiting now
- Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays — Recruiting now
- Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies — Recruiting now
- Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers — Running, not enrolling
- Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — Available (expanded access)
- Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications — Stopped early
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer — Running, not enrolling
- Avatrombopag vs. Placebo for CIT in GI Malignancies — Running, not enrolling
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors — Running, not enrolling
- A Study of PHN-010 in Patients With Advanced Solid Tumors — Stopped early
- A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling
- Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN — Withdrawn before enrolling
- A Study of Oraxol in Subjects With Cutaneous Angiosarcoma — Completed
- Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses — Completed
- A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 — Stopped early